Diabetes clinical decision-making in patients at risk: Taking patient complexity into account

2011 Boyle, 2010, Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence, Population Health metrics 8, 29, 10.1186/1478-7954-8-29 Tuomilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N Engl J Med, 344, 1343, 10.1056/NEJM200105033441801 Geiss, 2006, Changes in incidence of diabetes in U.S. adults, 1997-2003, Am J Prev Med, 30, 371, 10.1016/j.amepre.2005.12.009 Lutsey, 2010, Interactions between race/ethnicity and anthropometry in risk of incident diabetes: the multi-ethnic study of atherosclerosis, Am J Epidemiol, 172, 197, 10.1093/aje/kwq100 CDC, CDC Wonder (the Healthy People 2010 Database), 2010 Barker, 2011, Geographic distribution of diagnosed diabetes in the U.S.: a diabetes belt, American Journal of preventive medicine, 40, 434, 10.1016/j.amepre.2010.12.019 MMWR, Differences in Prevalence of Obesity Among Black, White, and Hispanic Adults --- United States, 2006--2008 Garber, 2008, Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists, Endocr Pract, 14, 933, 10.4158/EP.14.7.933 Standards of medical care in diabetes--2012. Diabetes Care 35 Suppl 1 (2012) S11-63 Sacks, 2011, Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus, Diabetes Care, 34, e61, 10.2337/dc11-9998 2009, Diabetes Care, 32, 1327, 10.2337/dc09-9033 1998, Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 1998, Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, The New England Journal of medicine, 359, 1577, 10.1056/NEJMoa0806470 Handelsman, 2011, American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan, Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 17, 1, 10.4158/EP.17.S2.1 Bloomgarden, 2011, Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids, Journal of Diabetes, 3, 257, 10.1111/j.1753-0407.2011.00161.x Defronzo, 2009, From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, Diabetes, 58, 773, 10.2337/db09-9028 S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, and D.R. Matthews, Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) Handelsman, 2011, American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary, Endocr Pract, 17, 287, 10.4158/EP.17.2.287 Ismail-Beigi, 2011, Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials, Annals of Internal Medicine, 154, 554, 10.7326/0003-4819-154-8-201104190-00007 Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 15, 540, 10.4158/EP.15.6.540 van Bruggen, 2009, Clinical inertia in general practice: widespread and related to the outcome of diabetes care, Fam Pract, 26, 428, 10.1093/fampra/cmp053 Bolen, 2009, Factors associated with intensification of oral diabetes medications in primary care provider-patient dyads: a cohort study, Diabetes Care, 32, 25, 10.2337/dc08-1297 Turner, 1999, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group., JAMA, 281, 2005, 10.1001/jama.281.21.2005 Kahn, 2006, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, N Engl J Med, 355, 2427, 10.1056/NEJMoa066224 Yki-Jarvinen, 2007, ADOPT: lessons from comparison of glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, Curr Diab Rep, 7, 173, 10.1007/s11892-007-0028-0 Kahn, 2008, Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT), Diabetes Care, 31, 845, 10.2337/dc07-2270 Stephenson, 2011, Diabetes drug may be associated with increase in risk of bladder cancer, JAMA, 306, 143, 10.1001/jama.2011.939 Hirsch, 2005, Insulin analogues, N Engl J Med, 352, 174, 10.1056/NEJMra040832 Owens, 2011, Insulin preparations with prolonged effect, Diabetes Technol Ther, 13, S5, 10.1089/dia.2011.0068 Garber, 2012, Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial, Lancet, 379, 1498, 10.1016/S0140-6736(12)60205-0 Heise, 2011, A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial, Diabetes Care, 34, 669, 10.2337/dc10-1905 Niskanen, 2012, Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial, European journal of endocrinology/ European Federation of Endocrine Societies, 167, 287, 10.1530/EJE-12-0293 Russell-Jones, 2012 B. Zinman, A. Philis-Tsimikas, B. Cariou, Y. Handelsman, H.W. Rodbard, T. Johansen, L. Endahl, and C. Mathieu, Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care (2012) R. Ratner, S.C. Gough, C. Mathieu, S.D. Prato, B. Bode, H. Mersebach, L. Endahl, and B. Zinman, Hypoglycaemia Risk With Insulin Degludec Compared With Insulin Glargine in Type 2 and Type 1 Diabetes: A Pre-planned Meta-Analysis of Phase 3 Trials. Diabetes, Obesity & Metabolism (2012) R.M. Bergenstal, J. Rosenstock, R.F. Arakaki, M.J. Prince, Y. Qu, V.P. Sinha, D.C. Howey, and S.J. Jacober, A Randomized, Controlled Study of Once Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care (2012) Rodbard, 2009, Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control, Endocr Pract, 15, 540, 10.4158/EP.15.6.540 Rodbard, 2010, Adding noninsulin antidiabetic drugs to metformin therapy for type 2 diabetes, JAMA, 304, 405, 10.1001/jama.2010.1021 Lorber, 2012, GLP-1 Receptor Agonists: Effects on Cardiovascular Risk Reduction, Cardiovascular Therapeutics, 10.1111/cdr.12000 Cariou, 2012, Harnessing the incretin system beyond glucose control: Potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes, Diabetes & Metabolism, 38, 298, 10.1016/j.diabet.2012.04.003